ARP Global Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.7M Buy
30,001
+1,706
+6% +$2.01M 5.09% 8
2026
Q2
$33.9M Buy
28,295
+22,760
+411% +$23.3M 14.63% 1
2026
Q1
$5.09M Sell
5,535
-10,305
-65% -$10.4M 2.99% 11
2025
Q4
$17M Buy
+15,840
New +$15.1M 5.14% 6

Other funds holding LLY

ARP Global Capital's LLY Position: Q3 2026 in Review

ARP Global Capital increased its Eli Lilly (LLY) stake by 6% in Q3 2026, buying an estimated $2.01M and bringing the position to 30,001 shares worth $34.7M. The position accounts for 5.09% of the portfolio, ranked #8.

ARP Global Capital first reported a position in LLY in Q4 2025 and has held it in 4 quarters since. 4,616 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • ARP Global Capital held 30,001 shares of Eli Lilly worth $34.7M as of Q3 2026.
  • ARP Global Capital bought 1,706 Eli Lilly shares in Q3 2026, an estimated $2.01M.
  • Eli Lilly made up 5.09% of ARP Global Capital's portfolio in Q3 2026, its #8 holding.
  • ARP Global Capital first reported a position in Eli Lilly in Q4 2025 and has held it in 4 quarters since.
  • 4,616 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on ARP Global Capital's 13F filing for Q3 2026, filed 13 Nov 2026.